New research could lead to a simple blood test for brain tumors
University of Bristol research could lead to better detection of the most common type of malignant brain cancer.
Aug 2, 2022
0
93
University of Bristol research could lead to better detection of the most common type of malignant brain cancer.
Aug 2, 2022
0
93
Glioblastoma multiforme (GBM) is one of the most aggressive, fast-growing tumor types, and the most common cancer of the brain with a median overall survival of approximately 15 months. Despite recent advances in treatment ...
Aug 2, 2022
0
5
Certain cells from glioblastomas, the most aggressive form of brain tumors, mimic characteristics and movement strategies of immature neurons to colonize the brain. Fundamental new results from researchers at Heidelberg University ...
Aug 1, 2022
0
42
A gene that University of Virginia (UVA) Health researchers have discovered is responsible for the deadliest type of brain tumor is also responsible for two forms of childhood cancer, the scientists have found.
Jul 28, 2022
0
857
Immunotherapy has revolutionized treatment for many forms of cancer, but glioblastoma multiforme (GBM), the most common and deadly form of brain cancer, has remained untouched. GBM tumors are sometimes referred to as "cold"—that ...
Jul 11, 2022
0
59
Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Center, providing hope for a cancer that is highly lethal.
Jun 22, 2022
0
101
An innovative light-activated therapy developed at The Institute of Cancer Research, London, could help detect and treat an aggressive brain cancer type, a new study shows.
Jun 20, 2022
0
112
A drug carrier able to reach the brain, bind to an aggressive type of tumor called glioblastoma multiforme, and release a chemotherapeutic agent has been tested for the first time by Brazilian researchers. According to an ...
Jun 14, 2022
0
34
All of the newly diagnosed glioblastoma multiforme patients enrolled in a Phase 1 clinical trial at the University of Alabama at Birmingham have exceeded both their median and expected progression-free survivals. Two patients, ...
Jun 10, 2022
0
9
Two studies led by The University of Texas MD Anderson Cancer Center that shed new light on the potential of the gut microbiome as a targetable biomarker to improve responses to immunotherapy were presented today at the 2022 ...
Jun 6, 2022
0
2